Vol 70, No 6 (2020)
Review paper
Published online: 2020-12-04

open access

Page views 513
Article views/downloads 592
Get Citation

Connect on Social Media

Connect on Social Media

Immunotherapy in sarcoma

Hanna Koseła-Paterczyk1
Nowotwory. Journal of Oncology 2020;70(6):296-302.


The introduction of immunotherapy with checkpoint inhibitors into clinical practice has radically changed the treatment and prognosis of patients with cancer. This treatment is also extensively studied in patients diagnosed with advanced sarcomas, where the number of effective therapies is limited. The following review presents the latest reports on the use of immunotherapy in the treatment of patients with sarcomas.

Article available in PDF format

View PDF Download PDF file


  1. Casali PG, Abecassis N, Aro HT, et al. ESMO Guidelines Committee and EURACAN, ESMO Guidelines Committee and EURACAN. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018; 29(Suppl 4): iv51–iv67.
  2. Casali PG, Bielack S, Abecassis N, et al. ESMO Guidelines Committee, PaedCan and ERN EURACAN. Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018; 29(Suppl 4): iv79–iv95.
  3. McCarthy EF. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J. 2006; 26: 154–158.
  4. Lee A, Huang P, DeMatteo RP, et al. Immunotherapy for Soft Tissue Sarcoma: Tomorrow Is Only a Day Away. Am Soc Clin Oncol Educ Book. 2016; 35: 281–290.
  5. Kim JR, Moon YJ, Kwon KS, et al. Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. PLoS One. 2013; 8(12): e82870.
  6. D'Angelo SP, Shoushtari AN, Agaram NP, et al. Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Hum Pathol. 2015; 46(3): 357–365.
  7. Koirala P, Roth ME, Gill J, et al. Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma. Sci Rep. 2016; 6: 30093.
  8. Machado I, López-Guerrero JA, Scotlandi K, et al. Immunohistochemical analysis and prognostic significance of PD-L1, PD-1, and CD8+ tumor-infiltrating lymphocytes in Ewing's sarcoma family of tumors (ESFT). Virchows Arch. 2018; 472(5): 815–824.
  9. Kostine M, Cleven AHg, de Miranda NF, et al. Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype. Mod Pathol. 2016; 29(9): 1028–1037.
  10. van Erp AEM, Versleijen-Jonkers YMH, Hillebrandt-Roeffen MHS, et al. Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8 lymphocytes in primary sarcomas is subtype dependent. Oncotarget. 2017; 8(41): 71371–71384.
  11. Petitprez F, de Reyniès A, Keung EZ, et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature. 2020; 577(7791): 556–560.
  12. Martin-Broto J, Hindi N, Grignani G, et al. Facts and Hopes in Immunotherapy of Soft-Tissue Sarcomas. Clin Cancer Res. 2020; 26(22): 5801–5808.
  13. Tawbi HA, Burgess M, Bolejack V, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017; 18(11): 1493–1501.
  14. Burgess M, Bolejack V, Schuetze S, et al. Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): Final results of SARC028 expansion cohorts. Journal of Clinical Oncology. 2019; 37(15_suppl): 11015–11015.
  15. Keung EZ, Burgess M, Salazar R, et al. Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab. Clin Cancer Res. 2020; 26(6): 1258–1266.
  16. D'Angelo SP, Mahoney MR, Van Tine BA, et al. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol. 2018; 19(3): 416–426.
  17. Pollack SM, Redman MW, Baker KK, et al. Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma: A Phase 1/2 Nonrandomized Clinical Trial. JAMA Oncol. 2020 [Epub ahead of print].
  18. Martin-Broto J, Hindi N, Grignani G, et al. Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial. J Immunother Cancer. 2020; 8(2).
  19. Lazar AJF, Das P, Tuvin D, et al. Angiogenesis-promoting gene patterns in alveolar soft part sarcoma. Clin Cancer Res. 2007; 13(24): 7314–7321.
  20. Kummar S, Allen D, Monks A, et al. Cediranib for metastatic alveolar soft part sarcoma. J Clin Oncol. 2013; 31(18): 2296–2302.
  21. Mariuk-Jarema A, Koseła-Paterczyk H, Rogala P, et al. A durable complete response to immunotherapy in a patient with metastatic alveolar soft part sarcoma. Tumori. 2020 [Epub ahead of print]: 300891620928133.
  22. Conry A, Peters M, Fried DB, et al. Complete Response to Dual Immunotherapy in a Young Adult with Metastatic Alveolar Soft Part Sarcoma Enabled by a Drug Recovery Program in a Community Practice. J Adolesc Young Adult Oncol. 2020; 9(3): 449–452.
  23. Coyne GO SE, Moore N, et al. Phase II study of atezolizumab in patients with alveolar soft part sarcoma. Connective Tissue Oncology Society Annual Meeting. Abstr 3042818. Rome, 14–17 Nov 2018.
  24. Wilky BA, Trucco MM, Subhawong TyK, et al. Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial. Lancet Oncol. 2019; 20(6): 837–848.